TransMedics price target lowered to $125 from $200 at Oppenheimer
The Fly

TransMedics price target lowered to $125 from $200 at Oppenheimer

Oppenheimer lowered the firm’s price target on TransMedics (TMDX) to $125 from $200 and keeps an Outperform rating on the shares following quarterly results. The firm notes TransMedics reported quarterly revenue of $108.8M, below its/consensus $117.1M/$115.0M estimates.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App